Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reissued by Truist Financial in a research report issued on Tuesday, Benzinga reports. They currently have a $1,200.00 target price on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 16.37% from the stock’s current price.

Several other brokerages also recently commented on REGN. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Barclays boosted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Wells Fargo & Company reiterated an “overweight” rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,118.62.

Regeneron Pharmaceuticals Trading Down 1.4 %

Shares of REGN opened at $1,031.15 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The firm has a market cap of $113.62 billion, a price-to-earnings ratio of 30.46, a PEG ratio of 3.72 and a beta of 0.12. The business’s fifty day moving average is $1,130.96 and its 200-day moving average is $1,034.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $8.79 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. West Paces Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.